



Additional Resources

Memo from Dr. Robert Temple, Acting Deputy Director of Drug Evaluation, FDA Center for Drug Evaluation and Research (April 29, 2016) ([Link](#))

Memo from Dr. Mitchell Mathis, Director of Psychiatry Drug Products Division, FDA Center for Drug Evaluation and Research (April 29, 2016) ([Link](#))

Summary Minutes, Meeting of the Psychopharmacologic Drugs Advisory Committee, FDA Center for Drug Evaluation and Research (March 29, 2016) ([Link](#))

The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin, Journal of Clinical Psychiatry (June 2017) ([Summary](#))